SS-31 Study Explained: Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with

Quick answer

For “Elamipretide Topical Ophthalmic Solution Treatment,” a phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.¹

This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.¹ Filipino readers should keep that finding tied to the cited study and verify any local product claim separately.

What is SS-31, in plain language?

For readers following Elamipretide Topical Ophthalmic Solution Treatment, the order matters: identify the study setting, read the result, then place the limitation beside it.

For “Elamipretide Topical Ophthalmic Solution Treatment,” the source describes a focused result: a phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.¹

Within “Elamipretide Topical Ophthalmic Solution Treatment,” the population and method are part of the answer: the randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point.¹

For “Elamipretide Topical Ophthalmic Solution Treatment,” the source also narrows the conclusion: this was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.¹

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What did the central study report?

A result becomes easier to trust when the Elamipretide Topical Ophthalmic Solution Treatment details stay visible. Population, method, outcome, and timeframe all belong near the conclusion.

For “Elamipretide Topical Ophthalmic Solution Treatment,” the paper’s main result was that in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.²

Within “Elamipretide Topical Ophthalmic Solution Treatment,” the study context keeps the conclusion precise: the study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.²

For “Elamipretide Topical Ophthalmic Solution Treatment,” that result does not erase its main limit: this is an animal study, and the result is for the combination, not elamipretide alone.²

What does the wider evidence add?

The practical reading of Elamipretide Topical Ophthalmic Solution Treatment is specific rather than dramatic. Keep the measured outcome, the comparison, and the study setting attached to one another.

For “Elamipretide Topical Ophthalmic Solution Treatment,” the central finding was specific: a phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.¹

Within “Elamipretide Topical Ophthalmic Solution Treatment,” that result came from this context: the randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point.¹

For “Elamipretide Topical Ophthalmic Solution Treatment,” the finding should stop here: this was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.¹

Which limits matter most?

The useful question in this Elamipretide Topical Ophthalmic Solution Treatment story is not whether the headline sounds impressive. It is whether the population, outcome, and comparison still match the cited source.

For “Elamipretide Topical Ophthalmic Solution Treatment,” the source describes a focused result: in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.²

Within “Elamipretide Topical Ophthalmic Solution Treatment,” the population and method are part of the answer: the study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.²

For “Elamipretide Topical Ophthalmic Solution Treatment,” the source also narrows the conclusion: this is an animal study, and the result is for the combination, not elamipretide alone.²

How does the catalog identity fit?

For readers following Elamipretide Topical Ophthalmic Solution Treatment, the order matters: identify the study setting, read the result, then place the limitation beside it.

For “Elamipretide Topical Ophthalmic Solution Treatment,” the paper’s main result was that in a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.³

Within “Elamipretide Topical Ophthalmic Solution Treatment,” the study context keeps the conclusion precise: the 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it.³

For “Elamipretide Topical Ophthalmic Solution Treatment,” that result does not erase its main limit: this was an open-label study with a small number of participants, and all knew they were receiving the active drug.³

For “Elamipretide Topical Ophthalmic Solution Treatment,” the study reported that in a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.⁴ For “Elamipretide Topical Ophthalmic Solution Treatment,” the main limit is equally important: the snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁴

For “Elamipretide Topical Ophthalmic Solution Treatment,” the central finding was specific: WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.⁵ For “Elamipretide Topical Ophthalmic Solution Treatment,” the finding should stop here: appearance alone cannot authenticate a product or establish a research outcome.⁵

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers take away?

A result becomes easier to trust when the Elamipretide Topical Ophthalmic Solution Treatment details stay visible. Population, method, outcome, and timeframe all belong near the conclusion.

For “Elamipretide Topical Ophthalmic Solution Treatment,” the central finding was specific: SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.⁶

Within “Elamipretide Topical Ophthalmic Solution Treatment,” that result came from this context: the FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.⁶

For “Elamipretide Topical Ophthalmic Solution Treatment,” the finding should stop here: this is a description of its mechanism of action from regulatory and laboratory sources.⁶

For “Elamipretide Topical Ophthalmic Solution Treatment,” researchers found that the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁷ For “Elamipretide Topical Ophthalmic Solution Treatment,” one caution belongs beside that result: a portal record applies to the exact product or establishment named in that record.⁷

Bottom line

For “Elamipretide Topical Ophthalmic Solution Treatment,” the clearest reading is that a phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.¹

In the “Elamipretide Topical Ophthalmic Solution Treatment” discussion, this was an open-label study with a small number of participants, and all knew they were receiving the active drug.³ For Filipino readers, the research result and the exact local product record remain separate checks.

That approach keeps SS-31 informative without turning one study into personal advice, a universal promise, or proof about a catalog product.

Frequently asked questions

What is the short answer about SS-31?

For “Elamipretide Topical Ophthalmic Solution Treatment,” the cited source gives a focused answer: a phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.¹ The conclusion stays tied to that study’s population, method, and measured outcome.

Does one positive result settle the whole topic?

For “Elamipretide Topical Ophthalmic Solution Treatment,” no single result settles the whole topic. This was an open-label study with a small number of participants, and all knew they were receiving the active drug.³ A useful result can remain narrow without being dismissed or promoted as a universal benefit.

Why does the study context matter?

Within “Elamipretide Topical Ophthalmic Solution Treatment,” the study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.² Changing the population, comparison, formulation, or endpoint would change the question, so those details belong beside the finding.

What should Filipino readers verify?

For “Elamipretide Topical Ophthalmic Solution Treatment,” in a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.³ Check the exact name and record shown by the official source instead of assuming that a familiar molecule name covers every listing.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In this Elamipretide Topical Ophthalmic Solution Treatment guide, the cards are live catalog references for navigation. They do not prove study equivalence, turn research into a product claim, or suggest that the two items should be used together.⁸

Sources

Footnotes

1. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.. The randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point. This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

2. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.. The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy. This is an animal study, and the result is for the combination, not elamipretide alone. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

3. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

4. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints. ↩ ↩²

5. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩²

6. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³

7. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩²

8. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.; Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩